Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633146 | 0.98 | KCNH2 (0.58) | KCNH2DRD2DRD3HTR7HTR1A | |
| SCHEMBL16633520 | 0.83 | DRD2 (0.59) | KCNH2DRD2DRD3HTR7HTR1A | |
| SCHEMBL16634117 | 0.80 | DRD2 (0.54) | KCNH2DRD2DRD3HTR7HTR1A | |
| SCHEMBL13499598 | 0.79 | DRD2 (0.51) | DRD2DRD3HTR7HTR2A | |
| SCHEMBL16633399 | 0.79 | DRD2 (0.58) | DRD2DRD3HTR1AHTR2ADRD4 | |
| SCHEMBL4525555 | 0.78 | KCNH2 (1.00) | KCNH2DRD2HTR7HTR1AHTR2A | |
| SCHEMBL16633483 | 0.77 | DRD2 (0.59) | DRD2DRD3HTR7HTR1AHTR2A | |
| SCHEMBL30767216 | 0.77 | KCNH2 (0.90) | KCNH2DRD2HTR7HTR1AHTR2A | |
| SCHEMBL16634073 | 0.77 | HTR7 (0.71) | KCNH2DRD2DRD3HTR7SIGMAR1 | |
| SCHEMBL15748029 | 0.76 | KCNH2 (0.58) | KCNH2DRD2DRD3HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | claimed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | claimed |
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | HTR5A, HTR3C, HTR3A | KCNH2 169/4885DRD2 80/4885DRD3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.